New horizons in osteoarthritis

Age and Ageing

Volumn 42, Issue 3, 2013, Pages 272-278

  Wenham, Claire Y J ^a   Conaghan, Philip G ^a  

^a Chapel Allerton Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; BRADYKININ ANTAGONIST; CALCITONIN; CHONDROITIN; CORTICOSTEROID; DULOXETINE; GLUCOSAMINE; HYALURONIC ACID; ICATIBANT; METHOTREXATE; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; RISEDRONIC ACID; STRONTIUM; STRONTIUM RANELATE; TANEZUMAB; TAPENTADOL; TUMOR NECROSIS FACTOR INHIBITOR; ZOLEDRONIC ACID;

ACUPUNCTURE; ARTICLE; BONE PAIN; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAND OSTEOARTHRITIS; HOT FLUSH; HUMAN; INTRACELLULAR SIGNALING; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; LONG BONE; LYMPHOCYTIC INFILTRATION; MOLECULAR PATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLINT; SUBCHONDRAL BONE; WALKING AID;

ANALGESICS; ANTI-INFLAMMATORY AGENTS; ARTHRALGIA; DISABILITY EVALUATION; HUMANS; JOINTS; MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PAIN MEASUREMENT; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877017920     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/aft043     Document Type: Article

References (63)

1. Yelin E, Murphy L, Cisternas MG, Foreman AJ, Pasta DJ, Helmick CG. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum 2007; 56: 1397-407.
2. Da RR, Qin Y, Baeten D, Zhang Y. B cell clonal expansion and somatic hypermutation of Ig variable heavy chain genes in the synovial membrane of patients with osteoarthritis. J Immunol 2007; 178: 557-65.
3. Sakkas LI, Platsoucas CD. The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum 2007; 56: 409-24.
4. Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 2005; 44: 7-16.
5. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010; 6: 625-35.
6. Goldring MB. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 2001; 1: 817-29.
7. Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum 2010; 62: 647-57.
8. Schneider EM, Du W, Fiedler J et al. The (-765 G->C) promoter variant of the COX-2/PTGS2 gene is associated with a lower risk for end-stage hip and knee osteoarthritis. Ann Rheum Dis 2011; 70: 1458-60.
9. Valdes AM, Loughlin J, Timms KM et al. Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis. Am J Hum Genet 2008; 82: 1231-40.
10. Chapman K, Takahashi A, Meulenbelt I et al. A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5'UTR of GDF5 with osteoarthritis susceptibility. Hum Mol Genet 2008; 17: 1497-504.
11. Evangelou E, Chapman K, Meulenbelt I et al. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. Arthritis Rheum 2009; 60: 1710-21.
12. Miyamoto Y, Mabuchi A, Shi D et al. A functional polymorphism in the 5' UTR of GDF5 is associated with susceptibility to osteoarthritis. Nat Genet 2007; 39: 529-33.
13. Panoutsopoulou K, Southam L, Elliott KS et al. Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. Annals Rheum Dis 2011; 70: 864-7.
14. Zhai G, van Meurs JB, Livshits G et al. A genome-wide association study suggests that a locus within the ataxin 2 binding protein 1 gene is associated with hand osteoarthritis: the Treat-OA consortium. J Med Genet 2009; 46: 614-6.
15. Neogi T, Felson D, Niu J et al. Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. BMJ 2009; 339: b2844.
16. Hunter DJ. Advanced imaging in osteoarthritis. Bull NYU Hosp Jt Dis 2008; 66: 251-60.
17. Haugen IK, Lillegraven S, Slatkowsky-Christensen B et al. Hand osteoarthritis and MRI: development and first validation step of the proposed Oslo Hand Osteoarthritis MRI score. Ann Rheum Dis 2011; 70: 1033-8.
18. Peterfy CG, Guermazi A, Zaim S et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004; 12: 177-90.
19. Hunter DJ, Guermazi A, Lo GH et al. Evolution of semiquantitative whole joint assessment of knee OA: MOAKS (MRI Osteoarthritis Knee Score). Osteoarthritis Cartilage 2011; 19: 990-1002.
20. Conaghan PG, Hunter DJ, Maillefert JF, Reichmann WM, Losina E. Summary and recommendations of the OARSI FDA osteoarthritis Assessment of Structural Change Working Group. Osteoarthritis Cartilage 2011; 19: 606-10.
21. Roos EM, Dahlberg L. Positive effects of moderate exercise on glycosaminoglycan content in knee cartilage: a fourmonth, randomized, controlled trial in patients at risk of osteoarthritis. Arthritis Rheum 2005; 52: 3507-14.
22. Iagnocco A, Meenagh G, Riente L et al. Ultrasound imaging for the rheumatologist XXIX. Sonographic assessment of the knee in patients with osteoarthritis. Clin Exp Rheum 2010; 28: 643-6.
23. Keen HI, Wakefield RJ, Grainger AJ, Hensor EM, Emery P, Conaghan PG. Can ultrasonography improve on radiographic assessment in osteoarthritis of the hands? A comparison between radiographic and ultrasonographic detected pathology. Ann Rheum Dis 2008; 67: 1116-20.
24. Baker K, Grainger A, Niu J et al. Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann Rheum Dis 2010; 69: 1779-83.
25. Conaghan P. A MRI study of the extent of 'gold standard'-evaluated synovitis and its relationship to pain in osteoarthritis of the knee. Am Coll Rheumatol 2006, Abstract No 2094.
26. Haugen IK, Boyesen P, Slatkowsky-Christensen B, Sesseng S, van der Heijde D, Kvien TK. Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. Ann Rheum Dis 2012; 71: 899-904.
27. Kortekaas MC, Kwok WY, Reijnierse M, Watt I, Huizinga TW, Kloppenburg M. Pain in hand osteoarthritis is associated with inflammation: the value of ultrasound. Ann Rheum Dis 2010; 69: 1367-9.
28. Loeuille D, Chary-Valckenaere I, Champigneulle J et al. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum 2005; 52: 3492-501.
29. Zhang Y, Nevitt M, Niu J et al. Fluctuation of knee pain and changes in bone marrow lesions, effusions, and synovitis on magnetic resonance imaging. Arthritis Rheum 2011; 63: 691-9.
30. Conaghan PG, D'Agostino MA, Le Bars M et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis 2010; 69: 644-7.
31. Weinans H, Siebelt M, Agricola R, Botter SM, Piscaer TM, Waarsing JH. Pathophysiology of peri-articular bone changes in osteoarthritis. Bone 2012; 51: 190-6.
32. Felson DT, Chaisson CE, Hill CL et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001; 134: 541-9.
33. Zanetti M, Bruder E, Romero J, Hodler J. Bone marrow edema pattern in osteoarthritic knees: correlation between MR imaging and histologic findings. Radiology 2000; 215: 835-40.
34. Felson DT, Niu J, Guermazi A et al. Correlation of the development of knee pain with enlarging bone marrow lesions on magnetic resonance imaging. Arthritis Rheum 2007; 56: 2986-92.
35. Felson DT, McLaughlin S, Goggins J et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003; 139: 330-6.
36. Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther 2011; 13: 211.
37. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheu Dis 2008; 67: 1716-23.
38. Zhang W, Nuki G, Moskowitz RW et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476-99.
39. Conaghan PG, Dickson J, Grant RL. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ 2008; 336: 502-3.
40. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 2012; 32: 1491-502.
41. Doherty M, Hawkey C, Goulder M et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheu Dis 2011; 70: 1534-41.
42. Wenham CYJ, Grainger A, Hensor EM, Caperon AR, Ash ZR, Conaghan PG. Methotrexate for pain relief in osteoarthritisan open-label study. Rheumatology (Oxford) 2013; Jan 7 epub.
43. Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009; 29: 961-5.
44. Grunke M, Schulze-Koops H. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Ann Rheum Dis 2006; 65: 555-6.
45. Magnano MD, Chakravarty EF, Broudy C et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007; 34: 1323-7.
46. Maksymowych WP, Russell AS, Chiu P et al. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther 2012; 14: R206.
47. Verbruggen G, Wittoek R, Cruyssen BV, Elewaut D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 2012; 71: 891-8.
48. Chevalier X, Ravaud P, Maheu E et al. eds. A Randomized, Multicentre, Double Blind, Placebo-Controlled Trial of Anti TNF Alpha (adalimumab) in Refractory Hand Osteoarthritis: The Dora Study. Washington, USA: American College of Rheumatology; 2012.
49. Bingham CO III, Buckland-Wright JC, Garnero P et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006; 54: 3494-507.
50. Laslett LL, Dore DA, Quinn SJ, Winzenberg TM, Boon P, Jones G. Zolendronic acid reduces bone marrow lesions and knee pain over one year. Ann Rheum Dis 2012; 71: 1322-8.
51. Reginster J, Chapurlat R, Christiansen C, Genant H, Bellamy N, Bensen W. Structure modifying effects of strontium ranelate in knee osteoarthritis. Osteoporosis Int 2012; 23(Suppl. 2): S58.
52. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006; 54: 3205-11.
53. Karsdal M, Alexandersen P, John MR, Loeffler J, Arnold M, Azria M. Oral calcitonin demonstrated symptom-modifying efficacy and increased cartilage volume: results from a 2-year phase 3 trial in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2011; 19S1: S35.
54. Ashraf S, Walsh DA. Angiogenesis in osteoarthritis. Curr Opin Rheumatol 2008; 20: 573-80.
55. Walsh DA, Bonnet CS, Turner EL, Wilson D, Situ M, McWilliams DF. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage 2007; 15: 743-51.
56. Lane NE, Schnitzer TJ, Birbara CA et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010; 363: 1521-31.
57. Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011; 27: 2361-72.
58. Wild JE, Grond S, Kuperwasser B et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010; 10: 416-27.
59. Song IH, Althoff CE, Hermann KG et al. Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI. Ann Rheum Dis 2009; 68: 75-83.
60. Martel-Pelletier J, Wildi LM, Pelletier JP. Future therapeutics for osteoarthritis. Bone 2012; 51: 297-311.
61. Guermazi A, Burstein D, Conaghan P et al. Imaging in osteoarthritis. Rheum Dis Clin North Am 2008; 34: 645-87.
62. Eckstein F, Kunz M, Schutzer M et al. Two year longitudinal change and test-retest-precision of knee cartilage morphology in a pilot study for the osteoarthritis initiative. Osteoarthritis Cartilage 2007; 15: 1326-32.
63. Eckstein F, Wirth W. Quantitative cartilage imaging in knee osteoarthritis. Arthritis 2011; 2011: 475684.